Silencing or stimulation? siRNA delivery and the immune system.

  title={Silencing or stimulation? siRNA delivery and the immune system.},
  author={Kathryn A. Whitehead and James E. Dahlman and Robert S. Langer and Daniel G. Anderson},
  journal={Annual review of chemical and biomolecular engineering},
Since its inception more than a decade ago, the field of short interfering RNA (siRNA) therapeutics has demonstrated potential in the treatment of a wide variety of diseases. The power behind RNA interference (RNAi) therapy lies in its ability to specifically silence target genes of interest. As more biological data have become available, it has become evident that, in addition to mediating RNAi, siRNA molecules have the potential to potently induce the innate immune system. One of the… 

Figures and Tables from this paper

Triggering RNAi with multifunctional RNA nanoparticles and their delivery

Different types of RNAi therapeutic delivery strategies including multifunctional RNA nanoparticles are being developed, and a mini-review will briefly describe some of the current approaches.

RNA Interference: Molecular mechanism and milestone therapeutic applications

Modern understanding is focused on the mechanisms and therapeutic applications of RNAi, a set of reactions involving the sequence-specific degradation of targeted mRNA by short double-stranded RNA molecules.

Polymers in the Delivery of siRNA for the Treatment of Virus Infections

Viral diseases remain a major cause of death worldwide. Despite advances in vaccine and antiviral drug technology, each year over three million people die from a range of viral infections.

Polymers in the Delivery of siRNA for the Treatment of Virus Infections

A background around problems associated with the translation of siRNA as antiviral treatments is provided, the progress made in nucleic acid therapeutics is reviewed and the importance of combining physicochemical characterisation of the NPs with in vitro and in vivo data is addressed.

Controlled local delivery of RNA : regulating tissue morphogenesis

The local delivery of siRNA may hold just as much potential as systemic delivery with significantly reduced complications and could be combined with existing medical devices to improve patient outcomes by directly addressing pathologic problems.

Stability and immunogenicity properties of the gene-silencing polypurine reverse Hoogsteen hairpins.

Stability experiments revealed that PPRHs, unlike siRNAs, do not activate the innate inflammatory response, and a new type of molecule to decrease gene expression named polypurine reverse Hoogsteen hairpins that bind to polypyrimidine targets in the DNA was developed.

Nanoparticle-based delivery strategies of multifaceted immunomodulatory RNA for cancer immunotherapy.

Nanotechnology for in vivo targeted siRNA delivery.

Lipid and Polymer-Based Nanoparticle siRNA Delivery Systems for Cancer Therapy

This article reviews the strategies that have been developed to facilitate siRNA survival in the circulatory system, siRNA movement from the blood into tissues and the TME, targeted siRNA delivery to the tumor or specific cell types, cellular uptake, and escape from endosomal degradation.



Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA

It is reported that synthetic siRNAs formulated in nonviral delivery vehicles can be potent inducers of interferons and inflammatory cytokines both in vivo in mice and in vitro in human blood.

Drug Delivery–mediated Control of RNA Immunostimulation

It is demonstrated that innate immune activation caused by unmodified siRNA can have therapeutically relevant effects, and that these non-RNAi effects can be controlled through chemical modifications and drug delivery.

Misinterpreting the therapeutic effects of small interfering RNA caused by immune stimulation.

It is demonstrated that in a murine model of influenza infection, the antiviral activity of siRNA is due primarily to immune stimulation elicited by the active siRNA duplexes and is not the result of therapeutic RNA interference (RNAi) as previously reported.

siRNA and innate immunity.

The intracellular mechanisms of innate immune activation by siRNA, the design of appropriate sequences and chemical modification approaches, and suitable experimental methods for studying their effects are described, with a view toward reducing siRNA-mediated off-target effects.

Rational design of immunostimulatory siRNAs.

The introduction of a micro-RNA-like nonpairing uridine-bulge in the passenger strand robustly increased immunostimulatory activity on human immune cells, and the data suggest that this sequence modification coupled with structural modification differentially recruits human TLR8 over TLR7, and could have potential application in antiviral therapies.

Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo.

The therapeutic potential of LNA-modified siRNAs: reduction of off-target effects by chemical modification of the siRNA sequence.

This chapter will explore the limitations and possibilities of LNA-modified siRNA that may be used in future therapeutic applications, and initial studies show that minimal modifications with locked nucleic acids (LNA) help to reduce most of the unwanted side effects.

Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice.

Preclinical development of chemically modified siRNA targeting the essential cell-cycle proteins polo-like kinase 1 (PLK1) and kinesin spindle protein (KSP) in mice is described, suggesting a new methodology for targeting other key genes in cancer development with siRNA-based therapeutics.

Lack of interferon response in animals to naked siRNAs

It is shown here that it is possible to administer naked, synthetic siRNAs to mice and downregulate an endogenous or exogenous target without inducing an interferon response.

Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles

Evidence is provided of inducing an RNAi mechanism of action in a human from the delivered siRNA and the presence of an mRNA fragment that demonstrates that siRNA-mediated mRNA cleavage occurs specifically at the site predicted for anRNAi mechanism from a patient who received the highest dose of the nanoparticles.